
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3507137/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of pulmonary artery catheter balloon inflation on pulmonary hemodynamics. Cardiovascular Diagnosis and Therapy, 2022, 12, 37-41.	1.7	0
2	A Review of Pulmonary Arterial Hypertension Treatment in Extracorporeal Membrane Oxygenation: A Case Series of Adult Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842110690.	2.0	5
3	Pulmonary Hypertension and Air Pollution. Respiratory Medicine, 2022, , 179-186.	0.1	1
4	Impact of Esophageal Pressure Measurement on Pulmonary Hypertension Diagnosis in Patients With Obesity. Chest, 2022, 162, 684-692.	0.8	9
5	Predictors of survival in portopulmonary hypertension: a 20-year experience. European Journal of Gastroenterology and Hepatology, 2022, 34, 449-456.	1.6	7
6	Bilateral Pulmonary Emboli and Deep Venous Thrombi in Association With Chronic Inflammatory Demyelinating Polyneuropathy. Cureus, 2021, 13, e14802.	0.5	0
7	Disease-specific platelet signaling defects in idiopathic pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L739-L749.	2.9	6
8	Causes and Circumstances of Death in Portopulmonary Hypertension. Transplantation Direct, 2021, 7, e710.	1.6	9
9	Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension?. Journal of Heart and Lung Transplantation, 2021, 40, 614-622.	0.6	4
10	Novel Treatment Pathways in Pulmonary Arterial Hypertension. Methodist DeBakey Cardiovascular Journal, 2021, 17, 29.	1.0	6
11	The breath print represents a novel biomarker of malnutrition in pulmonary arterial hypertension: a proofâ€ofâ€concept study. Journal of Parenteral and Enteral Nutrition, 2021, 45, 1645-1652.	2.6	2
12	Cutaneous Iontophoresis of Vasoactive Medications in Patients with Scleroderma―Associated Pulmonary Arterial Hypertension. Microcirculation, 2021, , e12734.	1.8	0
13	Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery. European Respiratory Review, 2021, 30, 210166.	7.1	6
14	COVID-19 and postural tachycardia syndrome: a case series. European Heart Journal - Case Reports, 2021, 5, ytab325.	0.6	7
15	Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 131-141.	2.0	15
16	Is There Value in Repeating Inhaled Nitric Oxide Vasoreactivity Tests in Patients with Pulmonary Arterial Hypertension?. Lung, 2020, 198, 87-94.	3.3	7
17	Right heart catheterization for pulmonary hypertension during the coronavirus disease 2019 pandemic. Pulmonary Circulation, 2020, 10, 1-6.	1.7	4
18	Breath Metabolomics Provides an Accurate and Noninvasive Approach for Screening Cirrhosis, Primary, and Secondary Liver Tumors. Hepatology Communications, 2020, 4, 1041-1055.	4.3	32

#	Article	IF	CITATIONS
19	Repeatability of Pulmonary Pressure Measurements in Patients with Pulmonary Hypertension. Annals of the American Thoracic Society, 2020, 17, 1028-1030.	3.2	8
20	Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension. Chest, 2020, 158, 2546-2555.	0.8	11
21	Platelet glycolytic metabolism correlates with hemodynamic severity in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L562-L569.	2.9	11
22	Comparison of volatile organic compound profiles in exhaled breath versus plasma headspace in different diseases. Journal of Breath Research, 2020, 14, 036003.	3.0	5
23	Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. Integrated Blood Pressure Control, 2020, Volume 13, 15-29.	1.2	24
24	Methods to improve the yield of right heart catheterization in pulmonary hypertension. Respiratory Medicine: X, 2020, 2, 100015.	1.4	5
25	Reply: Will the Real Pulmonary Pressure Please Stand Up?. Annals of the American Thoracic Society, 2020, 17, 1341-1341.	3.2	Ο
26	Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies. Pulmonary Circulation, 2020, 10, 2045894020977025.	1.7	3
27	Treatment Barriers in Portopulmonary Hypertension. Hepatology, 2019, 69, 431-443.	7.3	34
28	Comparison of Different Methods to Estimate Cardiac Index in Pulmonary Arterial Hypertension. Circulation, 2019, 140, 705-707.	1.6	22
29	A pilot study on the kinetics of metabolites and microvascular cutaneous effects of nitric oxide inhalation in healthy volunteers. PLoS ONE, 2019, 14, e0221777.	2.5	5
30	Pulmonary Edema Following Initiation of Parenteral Prostacyclin Therapy for Pulmonary Arterial Hypertension. Chest, 2019, 156, 45-52.	0.8	5
31	Gasometric gradients between blood obtained from the pulmonary artery wedge and pulmonary artery artery positions in pulmonary arterial hypertension. Respiratory Research, 2019, 20, 6.	3.6	6
32	Microvascular involvement in systemic sclerosis and systemic lupus erythematosus. Microcirculation, 2019, 26, e12440.	1.8	38
33	Effect of abnormal right heart structures on the diagnosis of pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-8.	1.7	3
34	Is hyponatremia associated with mortality in pulmonary arterial hypertension?. Pulmonary Circulation, 2018, 8, 1-7.	1.7	4
35	Palliative care in pulmonary arterial hypertension: an underutilised treatment. European Respiratory Review, 2018, 27, 180069.	7.1	25
36	Serum Chloride Levels Track With SurvivalÂin Patients With Pulmonary ArterialÂHypertension. Chest, 2018, 154, 541-549.	0.8	24

#	Article	lF	CITATIONS
37	Pulse Oximetry and Arterial Oxygen Saturation during Cardiopulmonary Exercise Testing. Medicine and Science in Sports and Exercise, 2018, 50, 1992-1997.	0.4	24
38	Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1090-1093.	5.6	3
39	Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS ONE, 2018, 13, e0191869.	2.5	17
40	Effect of Weight on Parenteral Prostacyclin Analogues Dosing in Pulmonary Hypertension. Chest, 2017, 151, 1189-1192.	0.8	0
41	Different efficacy of inhaled and oral medications in pulmonary hypertension. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 334-337.	1.6	6
42	Changes in main pulmonary artery diameter during followâ€up have prognostic implications in pulmonary arterial hypertension. Respirology, 2017, 22, 1649-1655.	2.3	19
43	Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension?. Pulmonary Circulation, 2017, 7, 727-729.	1.7	4
44	Evaluation of left ventricular diastolic function profile in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. Clinical Cardiology, 2017, 40, 356-363.	1.8	9
45	Assessing the kinetics of microbubble appearance in cirrhotic patients using transthoracic saline contrastâ€enhanced echocardiography. Echocardiography, 2017, 34, 1439-1446.	0.9	14
46	Management of combined pre- and post-capillary pulmonary hypertension in advanced heart failure with reduced ejection fraction. Respiratory Medicine, 2017, 131, 94-100.	2.9	3
47	Toxicity risk from glucocorticoids in sarcoidosis patients. Respiratory Medicine, 2017, 132, 9-14.	2.9	102
48	Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil. Cardiovascular Therapeutics, 2017, 35, e12281.	2.5	9
49	Impact of Intrathoracic Pressure in the Assessment of Pulmonary Hypertension in Overweight Patients. Annals of the American Thoracic Society, 2017, 14, 1861-1863.	3.2	17
50	A review of imaging modalities in pulmonary hypertension. Annals of Thoracic Medicine, 2017, 12, 61.	1.8	51
51	Lung or Heart-Lung Transplant in Pulmonary Arterial Hypertension: What Is the Impact of Systemic Sclerosis?. Experimental and Clinical Transplantation, 2017, 15, 676-684.	0.5	5
52	Novel Methods in Pulmonary Hypertension Phenotyping in the Age of Precision Medicine (2015 Grover) Tj ETQq	0 0 0 rgBT 1.7	- /Overlock 10
53	Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis. Respiratory Medicine. 2016. 117. 65-72.	2.9	30

<sup>&</sup>lt;sup>54</sup> Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials. Chest, 2016, 149, 0.8 15

#	Article	IF	CITATIONS
55	Compression of adjacent anatomical structures by pulmonary artery dilation. Postgraduate Medicine, 2016, 128, 451-459.	2.0	22
56	Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 760-767.	0.6	22
57	What is the best approach to a high systolic pulmonary artery pressure on echocardiography?. Cleveland Clinic Journal of Medicine, 2016, 83, 256-260.	1.3	14
58	Predictors of mortality after transjugular portosystemic shunt. World Journal of Hepatology, 2016, 8, 520.	2.0	27
59	Hemodynamic Consequences of a Surgical Arteriovenous Fistula. Annals of the American Thoracic Society, 2016, 13, 288-291.	3.2	8
60	Treprostinil Iontophoresis in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1014-1016.	5.6	11
61	Lung transplantation in chronic obstructive pulmonary disease: patient selection and special considerations. International Journal of COPD, 2015, 10, 2137.	2.3	13
62	A 70-Year-Old Man With Large Cervical and Mediastinal Lymphadenopathies. Chest, 2015, 148, e8-e13.	0.8	4
63	Right Ventricular Echocardiographic Parameters Are Associated with Mortality after Acute Pulmonary Embolism. Journal of the American Society of Echocardiography, 2015, 28, 355-362.	2.8	69
64	Can We Better Estimate Resting Oxygen Consumption by Incorporating Arterial Blood Gases and Spirometric Determinations?. Respiratory Care, 2015, 60, 517-525.	1.6	4
65	The Effect of Thrombolytic Use and Mechanical Ventilation on Echocardiographic Parameters of Survival after Acute Pulmonary Embolism. Journal of the American Society of Echocardiography, 2015, 28, 846-847.	2.8	1
66	Peripheral Pulmonary Artery Stenosis as a Cause of Pulmonary Hypertension in Adults. Pulmonary Circulation, 2015, 5, 204-210.	1.7	30
67	Are Transcutaneous Oxygen and Carbon Dioxide Determinations of Value in Pulmonary Arterial Hypertension?. Microcirculation, 2015, 22, 249-256.	1.8	3
68	Cardiac Tamponade in Severe Pulmonary Hypertension. A Therapeutic Challenge Revisited. Annals of the American Thoracic Society, 2015, 12, 455-460.	3.2	8
69	Electrocardiographic Differences between COPD Patients Evaluated for Lung Transplantation With and without Pulmonary Hypertension. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 670-680.	1.6	9
70	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Perioperative management in patients with pulmonary hypertension. Annals of Thoracic Medicine, 2014, 9, 98.	1.8	14
71	Breath Analysis in Pulmonary Arterial Hypertension. Chest, 2014, 145, 551-558.	0.8	39
72	Significance of Main Pulmonary Artery Dilation on Imaging Studies. Annals of the American Thoracic Society, 2014, 11, 1623-1632.	3.2	63

5

#	Article	IF	CITATIONS
73	Heart rate slopes during 6-min walk test in pulmonary arterial hypertension, other lung diseases, and healthy controls. Physiological Reports, 2014, 2, e12038.	1.7	10
74	Beyond the evidence: treating pulmonary hypertension in the intensive care unit. Critical Care, 2014, 18, 524.	5.8	6
75	Sublingual Microcirculation in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2014, 11, 504-512.	3.2	29
76	Subcutaneous to Intravenous Prostacyclin Analog Transition in Pulmonary Hypertension. Journal of Cardiovascular Pharmacology, 2014, 63, 4-8.	1.9	12
77	Pharmacologic Management of Perioperative Pulmonary Hypertension. Journal of Cardiovascular Pharmacology, 2014, 63, 375-384.	1.9	13
78	Prognostic Value of Echocardiographic Changes in Patients with Pulmonary Arterial Hypertension Receiving Parenteral Prostacyclin Therapy. Journal of the American Society of Echocardiography, 2014, 27, 733-741.e2.	2.8	27
79	Effects of interventions on survival in acute respiratory distress syndrome: an umbrella review of 159 published randomized trials and 29 meta-analyses. Intensive Care Medicine, 2014, 40, 769-787.	8.2	117
80	Electrocardiography at Diagnosis and Close to the Time of Death in Pulmonary Arterial Hypertension. Annals of Noninvasive Electrocardiology, 2014, 19, 258-265.	1.1	31
81	Why patients who die of worsening pulmonary arterial hypertension are not on parenteral prostacyclin analog treatment?. Journal of Heart and Lung Transplantation, 2014, 33, 221.	0.6	3
82	Linking Autoimmunity and Pulmonary Arterial Hypertension. Science Translational Medicine, 2014, 6, .	12.4	0
83	Too Much of a Good Channel in Pulmonary Arterial Hypertension. Science Translational Medicine, 2014, 6, .	12.4	0
84	Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice. International Journal of Clinical and Experimental Pathology, 2014, 7, 1935-46.	0.5	13
85	Causes and Circumstances of Death in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 365-369.	5.6	186
86	State of the evidence: mechanical ventilation with PEEP in patients with cardiogenic shock. Heart, 2013, 99, 1812-1817.	2.9	47
87	Novel device (AirWave) to assess endotracheal tube migration: A pilot study. Journal of Critical Care, 2013, 28, 535.e1-535.e8.	2.2	6
88	Clinical Characterization and Survival of Patients with Borderline Elevation in Pulmonary Artery Pressure. Pulmonary Circulation, 2013, 3, 916-925.	1.7	49
89	Pulmonary hypertension survival effects and treatment options in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2013, 19, 652-661.	2.6	23
90	Perioperative Management of the Patient with Pulmonary Hypertension. , 2013, , 137-154.		1

#	Article	IF	CITATIONS
91	Ventricular fibrillation caused by extrinsic compression of the left main coronary artery. Heart, 2013, 99, 895-896.	2.9	6
92	Pericardial Effusion in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 467-477.	1.7	41
93	Spleen Size in Idiopathic and Heritable Pulmonary Arterial Hypertension. Respiration, 2013, 85, 391-399.	2.6	11
94	Nitric Oxide Deficiency in Pulmonary Hypertension: Pathobiology and Implications for Therapy. Pulmonary Circulation, 2013, 3, 20-30.	1.7	67
95	Geometry of the Randomized Evidence for Treatments of Pulmonary Hypertension. Cardiovascular Therapeutics, 2013, 31, e138-46.	2.5	15
96	Value of Impedance Cardiography during 6â€Minute Walk Test in Pulmonary Hypertension. Clinical and Translational Science, 2013, 6, 474-480.	3.1	13
97	Intrapulmonary shunt confirmed by intracardiac echocardiography in the diagnosis of hepatopulmonary syndrome. Hepatology, 2013, 58, 1514-1515.	7.3	12
98	Response. Chest, 2013, 143, 273-274.	0.8	2
99	Is Pulmonary Arterial Hypertension a Cancer?. Science Translational Medicine, 2013, 5, .	12.4	1
100	Estimation of Blood Flow Resistance in the Lung with MRI. Science Translational Medicine, 2013, 5, .	12.4	1
101	Heart Versus Lungs in Hypertension Tug-of-War. Science Translational Medicine, 2013, 5, .	12.4	0
102	A Coat Connects Obesity with Heart Disease. Science Translational Medicine, 2013, 5, .	12.4	0
103	Can Antacids Affect the Heart?. Science Translational Medicine, 2013, 5, .	12.4	0
104	A Reflex Cause of Pulmonary Hypertension. Science Translational Medicine, 2013, 5, .	12.4	0
105	Nitric Oxide Signaling at the Heart of the Matter. Science Translational Medicine, 2013, 5, .	12.4	0
106	Leptin Levels Predict Survival in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2012, 2, 214-219.	1.7	18
107	Subdural Hematomas in Pulmonary Arterial Hypertension Patients Treated with Protacyclin Analogs. Pulmonary Circulation, 2012, 2, 518-521.	1.7	6
108	Prevalence and Prognostic Value of Left Ventricular Diastolic Dysfunction in Idiopathic and Heritable Pulmonary Arterial Hypertension. Chest, 2012, 141, 1457-1465.	0.8	66

#	Article	IF	CITATIONS
109	Congenital Heart Disease and Pulmonary Hypertension. Heart Failure Clinics, 2012, 8, 427-445.	2.1	12
110	Pulmonary Vascular Changes In Obese Leptin-Deficient (ob/ob) Mice. , 2012, , .		0
111	Determination Of Hemodynamic Parameters During 6-Minute Walk Test In Pulmonary Hypertension. , 2012, , .		1
112	Spleen Size In Idiopathic And Heritable Pulmonary Arterial Hypertension: Correlation With Disease Severity And Outcomes. , 2012, , .		0
113	Pulmonary hypertension before first and second lung transplantation. Clinical Transplantation, 2012, 26, 672-678.	1.6	О
114	Partial anomalous pulmonary venous connection and pulmonary arterial hypertension. Respirology, 2012, 17, 957-963.	2.3	37
115	Pulmonary Medicine. , 2012, , 122-155.		0
116	Value of Impedance Cardiography in Patients Studied for Pulmonary Hypertension. Lung, 2011, 189, 369-375.	3.3	37
117	Effect of Balloon Inflation Volume on Pulmonary Artery Occlusion Pressure in Patients With and Without Pulmonary Hypertension. Chest, 2011, 139, 115-121.	0.8	39
118	Value of Impedance Cardiography in Pulmonary Hypertension. Chest, 2010, 138, 359A.	0.8	1
119	Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survival. Journal of Heart and Lung Transplantation, 2010, 29, 865-872.	0.6	41
120	Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respiratory Medicine, 2010, 104, 481-496.	2.9	93
121	Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies. Therapeutic Advances in Respiratory Disease, 2010, 4, 289-312.	2.6	47
122	Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. International Journal of COPD, 2009, 4, 443.	2.3	49
123	Rituximab-Induced Hypersensitivity Pneumonitis. Respiration, 2009, 78, 225-229.	2.6	38
124	Successful use of high-frequency oscillator ventilation for acute respiratory distress syndrome with pneumomediastinum. Respiratory Medicine CME, 2009, 2, 173-175.	0.1	1
125	Bronchiectasis, a long-term sequela of ammonia inhalation: A case report and review of the literature. Burns, 2009, 35, 451-453.	1.9	27
126	Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis. Journal of Cystic Fibrosis, 2009, 8, 193-197.	0.7	26

#	Article	IF	CITATIONS
127	Endobronchial Band. Journal of Bronchology and Interventional Pulmonology, 2009, 16, 37-38.	1.4	1
128	INCIDENCE AND FACTORS ASSOCIATED WITH PULMONARY HYPERTENSION IN PATIENTS WITH ADVANCED LUNG DISEASE EVALUATED FOR LUNG TRANSPLANTATION. Chest, 2009, 136, 61S.	0.8	0
129	A FAMILY HISTORY OF RESPIRATORY DISEASES IS PREDICTIVE OF AN INCREASED FREQUENCY OF ALPHA-1-ANTITRYPSIN DEFICIENCY. Chest, 2009, 136, 52S.	0.8	0
130	PREDICTORS FOR THE USE OF CARDIOPULMONARY BYPASS DURING LUNG TRANSPLANTATION. Chest, 2009, 136, 17S.	0.8	1
131	A 19-year-old man with progressive lung infiltrates. Cleveland Clinic Journal of Medicine, 2009, 76, 635-638.	1.3	1
132	Treatment of a ruptured saphenous vein graft pseudoaneurysm using a vascular plug. Catheterization and Cardiovascular Interventions, 2008, 71, 587-589.	1.7	9
133	Lack of Order. American Journal of Medicine, 2008, 121, 393-394.	1.5	0
134	THE MAJORITY OF ADULTS IDENTIFIED AS PI Z ALPHA-1-ANTITRYPSIN DEFICIENT ARE OVER THE AGE OF 50. Chest, 2008, 134, 27S.	0.8	0
135	Spherules, Hyphae, and Air-Crescent Sign. American Journal of the Medical Sciences, 2008, 335, 504-506.	1.1	9
136	Seizures as the first manifestation of chromosome 22q11.2 deletion syndrome in a 40-year old man: a case report. Journal of Medical Case Reports, 2007, 1, 167.	0.8	14